---
title: "From insight to impact: The strategic role of biomarkers in drug discovery and clinical trials"
image: https://info.olink.com/hubfs/olink-application-biomarker_discovery_to_clinical_utility.jpg
---

[![Olink.png](https://info.olink.com/hs-fs/hubfs/00%20-%20Campaign%20Assets/23-10%20Master%20Folder/Logos/Olink-Logotype_Black.png?width=1000&height=304&name=Olink-Logotype_Black.png "Olink.png")](http://olink.com)

## WHITE PAPER

 From insight to impact: The strategic role of biomarkers in drug discovery and clinical trials

 Discover how leading pharma experts are using biomarker-driven strategies

DOWNLOAD WHITE PAPER

## About the content

In today’s data-driven drug development landscape, biomarkers have become powerful strategic assets—helping translate biological insights into measurable impact across the drug development and clinical trial pipeline. 

In this white paper, experts from AstraZeneca, Johnson & Johnson, and Takeda share their perspectives on how biomarker insights can strengthen target selection, enable earlier and more confident go/no-go decisions, and optimize patient segmentation. 

**Read the white paper** and **watch the expert panel discussion** to discover how proteomics is driving greater efficiency and confidence in drug development. 

 

© 2026 Olink Proteomics AB, part of Thermo Fisher Scientific. Olink products and services are For Research Use Only. Not for use in diagnostic procedures.